John Tsai, Forcefield Therapeutics CEO
Forcefield Therapeutics to start £35M Series A in October after scooping ex-Novartis exec John Tsai as new CEO
Former Novartis chief medical officer John Tsai is now a biotech CEO, and one of his first priorities at London, UK-based cardiovascular biotech Forcefield Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.